| 05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
| 03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
| 31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
| 30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
| 30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
| 03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
| 31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
| 05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
| Carolyn Cross |
156,314,029 |
£20,320,824 |
| Nicolas Loebel |
3,538,991 |
£460,069 |
| Junaid Bajwa |
1,193,697 |
£155,181 |
| Jean Duvall |
1,163,529 |
£151,259 |
| Jean Charest |
353,356 |
£45,936 |
| Carolyn Cross |
119,258,222 |
£15,503,569 |
| M&G Plc |
67,254,901 |
£8,743,137 |
| hInsight-NX, LLC |
42,272,654 |
£5,495,445 |
| Robert Cross |
37,772,652 |
£4,910,445 |
| Albemarle Life Sciences Fund |
15,105,882 |
£1,963,765 |
| CRUX Asset Management |
9,298,090 |
£1,208,752 |
| Chelverton Asset Management |
7,957,311 |
£1,034,450 |
| 16:35 |
5,000 @ 13.00p |
| 16:35 |
4,552 @ 13.00p |
| 16:35 |
448 @ 13.00p |
| 14:00 |
50,000 @ 12.66p |
| 14:00 |
500 @ 13.00p |
| Chair |
Jean Charest |
| CEO |
Carolyn Cross |
Top of Page
You are here:
research